Is there a role for thioguanine therapy in IBD in 2017 and beyond?

Kirstin M. Taylor, Mark G. Ward, Paul A. Blaker, Miles P. Sparrow

Research output: Contribution to journalReview ArticleResearchpeer-review

6 Citations (Scopus)

Abstract

Introduction: Conventional thiopurines are effective for the maintenance of remission of Crohn’s disease and ulcerative colitis, however, up to half of patients are intolerant or unresponsive to these medications. Thioguanine is an alternative thiopurine that has shown efficacy in inflammatory bowel disease, and is particularly useful to circumvent certain side effects associated with conventional thiopurines, for example, pancreatitis. Its association with nodular regenerative hyperplasia of the liver has hindered its widespread use. Areas covered: We aim to outline the rational use of thioguanine, including safety monitoring, with particular regard to hepatotoxicity. A literature search was performed: PubMed was searched for full papers and abstracts published in English since January 2000 using the following terms, alone and in combination: ‘azathioprine’, ‘thiopurine’, ‘Crohn’s disease’, ‘inflammatory bowel disease’, ‘nodular regenerative hyperplasia’, ‘mercaptopurine’, ‘thioguanine’, ‘ulcerative colitis’. Further relevant papers were identified from the reference lists of selected papers. Expert commentary: Despite optimisation strategies such as metabolite measurements and the use of allopurinol, a significant proportion of patients will remain intolerant to thiopurines, especially those with allergic reactions, including pancreatitis. For this subgroup of patients we suggest that low dose thioguanine is an alternative to other therapies that are either parenteral or expensive.

Original languageEnglish
Pages (from-to)473-486
Number of pages14
JournalExpert Review of Gastroenterology & Hepatology
Volume11
Issue number5
DOIs
Publication statusPublished - 4 May 2017

Keywords

  • Azathioprine
  • conventional thiopurines
  • crohn’s disease
  • inflammatory bowel disease
  • mercaptopurine
  • nodular regenerative hyperplasia
  • thioguanine
  • ulcerative colitis

Cite this

@article{3ff37d1ae1d241f2847793119ce81635,
title = "Is there a role for thioguanine therapy in IBD in 2017 and beyond?",
abstract = "Introduction: Conventional thiopurines are effective for the maintenance of remission of Crohn’s disease and ulcerative colitis, however, up to half of patients are intolerant or unresponsive to these medications. Thioguanine is an alternative thiopurine that has shown efficacy in inflammatory bowel disease, and is particularly useful to circumvent certain side effects associated with conventional thiopurines, for example, pancreatitis. Its association with nodular regenerative hyperplasia of the liver has hindered its widespread use. Areas covered: We aim to outline the rational use of thioguanine, including safety monitoring, with particular regard to hepatotoxicity. A literature search was performed: PubMed was searched for full papers and abstracts published in English since January 2000 using the following terms, alone and in combination: ‘azathioprine’, ‘thiopurine’, ‘Crohn’s disease’, ‘inflammatory bowel disease’, ‘nodular regenerative hyperplasia’, ‘mercaptopurine’, ‘thioguanine’, ‘ulcerative colitis’. Further relevant papers were identified from the reference lists of selected papers. Expert commentary: Despite optimisation strategies such as metabolite measurements and the use of allopurinol, a significant proportion of patients will remain intolerant to thiopurines, especially those with allergic reactions, including pancreatitis. For this subgroup of patients we suggest that low dose thioguanine is an alternative to other therapies that are either parenteral or expensive.",
keywords = "Azathioprine, conventional thiopurines, crohn’s disease, inflammatory bowel disease, mercaptopurine, nodular regenerative hyperplasia, thioguanine, ulcerative colitis",
author = "Taylor, {Kirstin M.} and Ward, {Mark G.} and Blaker, {Paul A.} and Sparrow, {Miles P.}",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/17474124.2017.1294062",
language = "English",
volume = "11",
pages = "473--486",
journal = "Expert Review of Gastroenterology & Hepatology",
issn = "1747-4124",
publisher = "Taylor & Francis",
number = "5",

}

Is there a role for thioguanine therapy in IBD in 2017 and beyond? / Taylor, Kirstin M.; Ward, Mark G.; Blaker, Paul A.; Sparrow, Miles P.

In: Expert Review of Gastroenterology & Hepatology, Vol. 11, No. 5, 04.05.2017, p. 473-486.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Is there a role for thioguanine therapy in IBD in 2017 and beyond?

AU - Taylor, Kirstin M.

AU - Ward, Mark G.

AU - Blaker, Paul A.

AU - Sparrow, Miles P.

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Introduction: Conventional thiopurines are effective for the maintenance of remission of Crohn’s disease and ulcerative colitis, however, up to half of patients are intolerant or unresponsive to these medications. Thioguanine is an alternative thiopurine that has shown efficacy in inflammatory bowel disease, and is particularly useful to circumvent certain side effects associated with conventional thiopurines, for example, pancreatitis. Its association with nodular regenerative hyperplasia of the liver has hindered its widespread use. Areas covered: We aim to outline the rational use of thioguanine, including safety monitoring, with particular regard to hepatotoxicity. A literature search was performed: PubMed was searched for full papers and abstracts published in English since January 2000 using the following terms, alone and in combination: ‘azathioprine’, ‘thiopurine’, ‘Crohn’s disease’, ‘inflammatory bowel disease’, ‘nodular regenerative hyperplasia’, ‘mercaptopurine’, ‘thioguanine’, ‘ulcerative colitis’. Further relevant papers were identified from the reference lists of selected papers. Expert commentary: Despite optimisation strategies such as metabolite measurements and the use of allopurinol, a significant proportion of patients will remain intolerant to thiopurines, especially those with allergic reactions, including pancreatitis. For this subgroup of patients we suggest that low dose thioguanine is an alternative to other therapies that are either parenteral or expensive.

AB - Introduction: Conventional thiopurines are effective for the maintenance of remission of Crohn’s disease and ulcerative colitis, however, up to half of patients are intolerant or unresponsive to these medications. Thioguanine is an alternative thiopurine that has shown efficacy in inflammatory bowel disease, and is particularly useful to circumvent certain side effects associated with conventional thiopurines, for example, pancreatitis. Its association with nodular regenerative hyperplasia of the liver has hindered its widespread use. Areas covered: We aim to outline the rational use of thioguanine, including safety monitoring, with particular regard to hepatotoxicity. A literature search was performed: PubMed was searched for full papers and abstracts published in English since January 2000 using the following terms, alone and in combination: ‘azathioprine’, ‘thiopurine’, ‘Crohn’s disease’, ‘inflammatory bowel disease’, ‘nodular regenerative hyperplasia’, ‘mercaptopurine’, ‘thioguanine’, ‘ulcerative colitis’. Further relevant papers were identified from the reference lists of selected papers. Expert commentary: Despite optimisation strategies such as metabolite measurements and the use of allopurinol, a significant proportion of patients will remain intolerant to thiopurines, especially those with allergic reactions, including pancreatitis. For this subgroup of patients we suggest that low dose thioguanine is an alternative to other therapies that are either parenteral or expensive.

KW - Azathioprine

KW - conventional thiopurines

KW - crohn’s disease

KW - inflammatory bowel disease

KW - mercaptopurine

KW - nodular regenerative hyperplasia

KW - thioguanine

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85017552071&partnerID=8YFLogxK

U2 - 10.1080/17474124.2017.1294062

DO - 10.1080/17474124.2017.1294062

M3 - Review Article

VL - 11

SP - 473

EP - 486

JO - Expert Review of Gastroenterology & Hepatology

JF - Expert Review of Gastroenterology & Hepatology

SN - 1747-4124

IS - 5

ER -